The Week That Was In North Asia@Smartkarma: JDI, Renesas, Trade, Governance, and Mobis/Glovis
It was a "slow" week on Smartkarma with 'only' 165 pieces of research published, but it is school vacation week in Asia, with two days off in Hong...
139 Views
Takeda + Shire - Highly Accretive Merger Considering Takeda’s Core Earnings
Announcement – Takeda, on March 28, 2018, confirmed that it is officially considering making an offer for Shire (NASDAQ: SHPG) and that it has time...
222 Views
Takeda Considers Swallowing Shire, a Somewhat Surprising Move That Could Make Strategic Sense
Japanese pharma firm Takeda Pharmaceutical Co Ltd (4502 JP) said it is officially considering making an offer for diversified rare-disease-focused...
190 Views
Not All Players Are Equal in the Plasma Industry
According to Allied Market Research, the IVIG (intravenous IG) market was valued at US$7.86bn and is expected to reach US$12.36bn by 2022. IVIG is...
313 Views
Chugai Pharmaceutical (4519 JP): Emicizumab Gets PDUFA Data
Chugai Pharmaceutical (4519 JP) announced on August 24th that the US FDA has accepted its Biologics License Application (BLA) for emicizumab (emi)...
253 Views